Published in Proc Natl Acad Sci U S A on December 13, 2005
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest (2009) 3.17
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron (2014) 2.69
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One (2008) 2.33
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.73
The genetics of Parkinson disease. J Geriatr Psychiatry Neurol (2010) 1.69
What causes cell death in Parkinson's disease? Ann Neurol (2008) 1.66
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A (2009) 1.64
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J (2008) 1.62
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol (2009) 1.51
Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet (2011) 1.49
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology (2015) 1.43
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res (2009) 1.38
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci (2009) 1.36
Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem (2009) 1.36
Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta (2010) 1.34
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet (2012) 1.29
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem (2011) 1.22
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet (2011) 1.21
Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry (2010) 1.17
Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther (2007) 1.17
ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci (2012) 1.13
RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochem J (2014) 1.13
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol (2007) 1.08
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci (2014) 1.08
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav (2007) 1.07
Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One (2009) 1.07
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol (2009) 1.03
RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics (2007) 1.03
A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta (2009) 1.02
Leprosy as a genetic disease. Mamm Genome (2010) 1.02
Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta (2008) 1.01
LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener (2006) 1.00
Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS One (2012) 0.99
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis (2011) 0.99
Coordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5. Exp Neurobiol (2010) 0.98
Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegener (2009) 0.98
ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS One (2010) 0.98
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener Dis (2010) 0.95
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS One (2012) 0.95
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord (2011) 0.95
Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet (2012) 0.94
Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp Neurol (2006) 0.93
Parkin occurs in a stable, non-covalent, approximately 110-kDa complex in brain. Eur J Neurosci (2008) 0.92
Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Hum Mol Genet (2013) 0.92
Models for LRRK2-Linked Parkinsonism. Parkinsons Dis (2011) 0.91
Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci (2008) 0.91
Genetic factors and manganese-induced neurotoxicity. Front Genet (2014) 0.90
The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res (2010) 0.90
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal (2011) 0.90
Update on the functional biology of Lrrk2. Future Neurol (2008) 0.89
Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies. Parkinsons Dis (2011) 0.89
LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88
Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? Neurobiol Dis (2010) 0.88
LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp Mol Med (2013) 0.88
Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS One (2011) 0.87
Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol Aging (2014) 0.87
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Future Med Chem (2012) 0.86
Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb Perspect Med (2012) 0.86
Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem (2010) 0.86
Are heat shock proteins therapeutic target for Parkinson's disease? Int J Biol Sci (2006) 0.86
LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles. FEBS J (2009) 0.85
Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans. Int J Mol Sci (2013) 0.85
LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat Commun (2015) 0.84
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis (2014) 0.84
Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2). Mol Neurodegener (2014) 0.84
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol Dis (2013) 0.83
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Hum Mol Genet (2015) 0.83
α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Neurotoxicology (2011) 0.83
Interaction of LRRK2 with kinase and GTPase signaling cascades. Front Mol Neurosci (2014) 0.82
Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China. Genes Immun (2014) 0.82
Crosstalk Between Macroautophagy and Chaperone-Mediated Autophagy: Implications for the Treatment of Neurological Diseases. Mol Neurobiol (2014) 0.81
Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J Biol Chem (2014) 0.81
Intrabody and Parkinson's disease. Biochim Biophys Acta (2008) 0.80
LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS One (2014) 0.80
Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol (2010) 0.80
LRRK2 mutations and neurotoxicant susceptibility. Exp Biol Med (Maywood) (2015) 0.79
Parkinson's disease and enhanced inflammatory response. Exp Biol Med (Maywood) (2015) 0.79
Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration. Biochim Biophys Acta (2014) 0.79
Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. Antioxid Redox Signal (2014) 0.78
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Protein aggregation and neurodegenerative disease. Nat Med (2004) 9.51
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem (2004) 4.86
Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol (1996) 4.54
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med (2001) 4.22
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol (2005) 3.18
p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron (2005) 3.13
Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet (1999) 2.53
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem (2003) 2.42
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron (2004) 2.29
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci (2005) 2.06
Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology (2002) 2.03
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
LRRK2 mutations in Parkinson disease. Neurology (2005) 2.01
Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev (2002) 1.80
The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol (2004) 1.76
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75
An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol (2005) 1.64
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol (2005) 1.60
Genetics of Parkinson's disease. Curr Opin Neurol (2005) 1.59
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci (2001) 1.51
Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol (2005) 1.47
Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem (2002) 1.30
Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol (2005) 1.22
A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet (2005) 1.16
Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.16
Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol (1998) 1.10
Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol (2005) 1.02
Protein kinases linked to the pathogenesis of Parkinson's disease. Neuron (2004) 1.02
The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett (2005) 1.00
Genetics of Parkinson's disease. Ann Med (2005) 0.99
Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. Biochem Soc Trans (2005) 0.96
Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med (2003) 0.96
Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. Neurol Sci (2002) 0.89
Genes in familial parkinsonism and their role in sporadic Parkinson's disease. J Neurol (2004) 0.83
Genetics of parkinsonism. Curr Neurol Neurosci Rep (2005) 0.82
Presenilin function in APP processing. Ann N Y Acad Sci (2000) 0.81
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell (2011) 4.00
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol (2005) 3.89
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A (2006) 3.47
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A (2006) 3.41
Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci U S A (2002) 3.34
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron (2005) 3.13
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. Neuron (2007) 2.83
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet (2005) 2.72
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res (2008) 2.70
Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol (2008) 2.56
Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene (2004) 2.52
Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry (2002) 2.52
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol (2002) 2.47
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet (2007) 2.44
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem (2003) 2.26
Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol (2009) 2.24
Understanding microRNAs in neurodegeneration. Nat Rev Neurosci (2009) 2.22
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci U S A (2004) 2.20
Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci (2004) 2.17
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem (2002) 2.12
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry (2010) 2.11
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet (2005) 2.11
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci (2005) 2.06
Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol (2008) 2.03
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A (2004) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97